D-LL-37

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

1.	Infections 01/01/2011 - "This study demonstrates the ability and equivalence of D-LL-37 compared to L-LL-37 to promote bacterial twitching motility and inhibit biofilm formation, and protect against in vivo infection, and suggests that this peptide could be a critical advancement in the development of new treatments for P. "
2.	Fibrosis (Cirrhosis) 01/01/2016 - "This study aimed to determine the role of the vitamin D-LL-37 pathway in the pathogenesis and treatment in patients with cirrhosis and SBP. "
3.	Tuberculosis (Tuberculoses) 03/01/2011 - "Anti-tuberculosis activity of α-helical antimicrobial peptides: de novo designed L- and D-enantiomers versus L- and D-LL-37."
4.	Pseudomonas Infections 01/01/2011 - "Both L- and D-LL-37 protected Galleria mellonella in vivo against Pseudomonas infection, while NA-CATH:ATRA1-ATRA1 peptide did not. "